Search - tctmd.com

Displaying 1 - 20 of 67

Sort: Relevancy | Date

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

News Conference News AHA 2025

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Caitlin E. Cox

November 08, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

Presentation AHA 2024

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Presenter: Marcely Gimenes Bonatto

November 18, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Conference News AHA 2024

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

Caitlin E. Cox

November 18, 2024

News Conference News AHA 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

Shelley Wood

November 18, 2024

News Conference News AHA 2024

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

Shelley Wood

November 16, 2024

News Conference News AHA 2024

US Obesity Epidemic Continues to Skyrocket, With No End in Sight

Michael O'Riordan

November 15, 2024

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Todd Neale

November 17, 2023

Presentation AHA 2023

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Presenter: Jamie Kitt

November 17, 2023

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

Todd Neale

November 13, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

News Conference News AHA 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

L.A. McKeown

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

Presentation AHA 2023

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Presenter: Steven E. Nissen

November 11, 2023

News Conference News AHA 2023

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

Caitlin E. Cox

November 07, 2023

News Conference News AHA 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

L.A. McKeown

November 11, 2022

Advertisement

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Triple Agonist Appears Promising for Patients With Severe Hypertriglyceridemia

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Effects of Sacubitril-Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy: The SARAH Trial

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

ARNI Lessens Anthracycline Cardiotoxicity in High-Risk Patients: SARAH

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

US Obesity Epidemic Continues to Skyrocket, With No End in Sight

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

Lepodisiran: An Extended-Duration siRNA Targeting Lipoprotein(a)

Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content